Skip to main content
Premium Trial:

Request an Annual Quote

Nonlinear Dynamics Says It Won t Renew 2D Gel Software OEM Deal with Amersham

NEW YORK, July 18 - Nonlinear Dynamics announced today that it has decided not to renew its OEM agreement to supply Amersham Biosciences' proteomics group with 2D gel analysis software.

 

This means that Amersham will no longer use Nonlinear Dynamics software in its ImageMaster 2D, ImageMaster 2D Evolution, Ettan Progenesis Workstation or Ettan Progenesis Discovery products.

 

The company has had this OEM agreement with Amersham since 1996.

 

"However we feel that Nonlinear and Amersham Biosciences' priorities within proteomics have diverged over the past two years," said Will Dracup, Nonlinear Dynamics' CEO, in a statement. "We therefore felt it was no longer in our best interests to be represented by them within this market."

 

This disclosure follows Wednesday's announcement by Amersham and GeneBio that Amersham would integrate GeneBio's Melanie 2-D gel analysis software into the ImageMaster image analysis application

 

For the full story on this change, see BioInform.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.